SynthesisFrontiers in public health2025
Economic evaluations of RSV preventive strategies: a systematic review of cost-effectiveness and modeling approaches.
Synthesis in Frontiers in public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Case for Anti-IgE Vaccination.Allergy · 2026Review
- Review
- Evaluating respiratory syncytial virus immunization strategies for infants in Canada: A cost-utility analysis.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Respiratory syncytial virus (RSV) causes significant morbidity and mortality worldwide, particularly in high-risk groups. Despite the availability of preventive interventions, it is crucial to evaluate the economic benefits of these interventions. Methods: This systematic review assessed the cost-effectiveness and model structures of RSV prevention strategies, including vaccines and monoclonal antibodies, by analyzing studies published up to March 2025. Results: A total of 39 studies were included, comprising one cost-benefit analysis (CBA) and 38 cost-effectiveness analyses (CEAs), utilizing six different types of economic models. The incremental cost-effectiveness ratio (ICER) among the older adult population varied from $5,342 to $385,829 per quality-adjusted life year (QALY). One study demonstrated superior cost-effectiveness of a long-acting monoclonal antibody (LAMA) compared to a short-acting monoclonal antibody, with both being more economically favorable than maternal vaccines for pregnant women and neonates. The most sensitive variables were intervention efficacy, price, and immunity duration. Conclusion: Most RSV vaccines and monoclonal antibody interventions demonstrate cost-effectiveness in specific populations and settings. However, cost-effectiveness is highly influenced by intervention price, efficacy, duration, populations, and administration time. Systematic review registration: The protocol for this study has been registered with PROSPERO under the registration number CRD42024524720.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.